PFE

Pfizer Inc.

Healthcare · NYSE · Market cap $156.9bn

$29.58

as of 16 Oct 2026, 1% below its 52-week high

Screens as reasonably placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield: 5.81%Last 12 months of regular payments at today's price
Forward yield: 5.92%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover: 0.44×Pays 226% of earnings
Cash cover: 1.1×Free cash flow over dividends paid
5y dividend growth: +2.5% a yearLast cut in FY2009
Next ex-dividend date: Declared6 Nov 2026Quarterly dividend of $0.43

Compared with US companies in Drug Manufacturers - General (9)

Trailing yield is higher than all 8 other US companies in Drug Manufacturers - General.
5y dividend growth (as paid) is lower than all 7 other US companies in Drug Manufacturers - General with a 5y growth figure.

Quality

Moderate

Capacity to keep growing the dividend

Risk

Low

Signals of dividend-cut pressure

Trim

Moderate

How extended the valuation looks

Why Quality is 53

PFE against US companies in Drug Manufacturers - General (9)

Valuation against its own history

As of the last reported period (28 Jun 2026). P80 means the figure is higher than 80% of PFE’s past readings.

P/E-141.0×P1, good for this measure
Yield7.1%P96, good for this measure
FCF payout89.1%P37, neutral for this measure
Net debt / EBITDA38.03P41, neutral for this measure
DGR 5y2.2%P19, poor for this measure
ROIC1.0%P96, good for this measure

Open valuation history

Forecast your income with the PFE dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.